Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AKTX

AKTX - Akari Therapeutics PLC Stock Price, Fair Value and News

$0.97-0.03 (-3.00%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

AKTX Price Action

Last 30 days

-34.0%

Last 90 days

-69.9%

Trailing 12 Months

-68.2%

AKTX RSI Chart

AKTX Valuation

Market Cap

48.0B

Price/Earnings (Trailing)

-2.4K

Price/Sales (Trailing)

137.3K

EV/EBITDA

-3.9K

Price/Free Cashflow

-3.2K

AKTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AKTX Fundamentals

AKTX Revenue

Revenue (TTM)

367.9K

AKTX Earnings

Earnings (TTM)

-20.2M

Earnings Growth (Yr)

-88.95%

Earnings Growth (Qtr)

-35.79%

AKTX Profitability

EBT Margin

-3486.47%

Return on Equity

301.12%

Return on Assets

-737.27%

Free Cashflow Yield

-0.03%

AKTX Investor Care

Shares Dilution (1Y)

48.08%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230527.7K447.8K367.9K
2022000607.7K
Get all data in R, Python etc through our Historical Stock Data APIs

About Akari Therapeutics PLC

AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
 CEO
 WEBSITEakaritx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Akari Therapeutics PLC Frequently Asked Questions

What is the ticker symbol for Akari Therapeutics PLC? What does AKTX stand for in stocks?

AKTX is the stock ticker symbol of Akari Therapeutics PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akari Therapeutics PLC (AKTX)?

As of Fri Dec 20 2024, market cap of Akari Therapeutics PLC is 48.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKTX stock?

You can check AKTX's fair value in chart for subscribers.

Is Akari Therapeutics PLC a good stock to buy?

The fair value guage provides a quick view whether AKTX is over valued or under valued. Whether Akari Therapeutics PLC is cheap or expensive depends on the assumptions which impact Akari Therapeutics PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKTX.

What is Akari Therapeutics PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, AKTX's PE ratio (Price to Earnings) is -2382.87 and Price to Sales (PS) ratio is 137.33 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Akari Therapeutics PLC's stock?

In the past 10 years, Akari Therapeutics PLC has provided -0.499 (multiply by 100 for percentage) rate of return.